Skip to main content

Advertisement

Log in

The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus

  • Otology
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

The purpose of the study was to evaluate the effectiveness of caspofungin and voriconazole in the treatment of experimental Aspergillus otits media in an experimental rabbit model. A total of 30 New Zealand white rabbits were divided into four treatment groups and one control group. The rabbits were immunosuppressed by cyclophosphamide and triamcinolone acetonide. The right ear of each rabbit was infected by an injection of the inoculum of 0.1 ml (8.6 × 103 CFU/0.1 ml) of Aspergillus fumigatus into the middle ear cavity. At 72 h after the inoculation, amphotericin B 1 mg/kg per day (n = 6), itraconazole 10 mg/kg per day (n = 6), voriconazole 10 mg/kg per day (n = 6) and caspofungin 5 mg/kg per day (n = 6) were injected to each treatment group. No antifungal drug was administered to the control group (n = 6). Clinical and histopathological examination scores and microbiological analysis of middle ear mucosa were compared.There was statistically significant difference in the clinical scores, histopathological scores, and mean CFU/g between the treatment and control groups (P < 0.05). There was no statistically significant difference among the treatment groups in the clinical and histopathological scores, whereas there was statistically significant difference in the mean CFU/g (P < 0.05). The mean CFU/g of amphotericin B and caspofungin groups were similar and both were lower than the itraconazole and voriconazole groups. Also, the mean CFU/g of voriconazole group was lower than the itraconazole group (P < 0.05). Caspofungin and voriconazole were demonstrated at least as effective as amphotericin B and itraconazole. We suggest that caspofungin and voriconazole may be considered for the treatment of fungal infection of the ear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ohki M, Ito K, Ishimoto S (2001) Fungal mastoiditis in an immunocompetent adult. Eur Arch Otorhinolaryngol 258:106–108

    Article  PubMed  CAS  Google Scholar 

  2. Gussen R, Canalis RF (1982) Mucormycosis of the temporal bone. Ann Otol Rhinol Laryngol 91:27–32

    PubMed  CAS  Google Scholar 

  3. Blackledge FA, Newlands SD (2001) Blastomycosis of the petrous apex. Otolaryngol Head Neck Surg 124:347–349

    Article  PubMed  CAS  Google Scholar 

  4. Bhally HS, Shields C, Lin SY, Merz WG (2004) Otitis caused by Scedosporium apiospermum in an immunocompetent child. Int J Pediatr Otorhinolaryngol 68:975–978

    Article  PubMed  CAS  Google Scholar 

  5. Chang CY, Schell WA, Perfect JR, Hulka GF (2005) Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis. Laryngoscope 115:1065–1069

    Article  PubMed  Google Scholar 

  6. Maschmeyer G, Ruhnke M (2004) Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses 47:263–276

    Article  PubMed  CAS  Google Scholar 

  7. Slack CL, Watson DW, Abzug MJ, Shaw C, Chan KH (1999) Fungal mastoiditis in immunocompromised children. Arch Otolaryngol Head Neck Surg 125:73–75

    PubMed  CAS  Google Scholar 

  8. Patterson TF (2005) Advances and challenges in management of invasive mycoses. Lancet 366:1013–1025

    Article  PubMed  Google Scholar 

  9. Shao PL, Huang LM, Hsueh PR (2007) Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 30:487–495

    Article  PubMed  CAS  Google Scholar 

  10. Patterson TF, Miniter P, Ryan JL, Andriole VT (1988) Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis 158:415–422

    PubMed  CAS  Google Scholar 

  11. Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF (2000) Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 44:780–782

    Article  PubMed  CAS  Google Scholar 

  12. Sandhu P, Xu X, Bondiskey PJ et al (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48:1272–1280

    Article  PubMed  CAS  Google Scholar 

  13. Kirkpatrick WR, Vallor AC, McAtee RK et al (2005) Combination therapy with terbinafine and amphotericin B in a rabbit model ofexperimental invasive aspergillosis. Antimicrob Agents Chemother 49:4751–4753

    Article  PubMed  CAS  Google Scholar 

  14. Roffey SJ, Cole S, Comby P et al (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–741

    Article  PubMed  CAS  Google Scholar 

  15. Lewis RE, Prince RA, Chi J, Kontoyiannis DP (2002) Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208–3214

    Article  PubMed  CAS  Google Scholar 

  16. Barry B, Muffat-Joly M, Bauchet J et al (1996) Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 40:1977–1982

    PubMed  CAS  Google Scholar 

  17. National Committee for Clinical Laboratory Standards: reference method for broth dilution antifungal susceptibility testing of yeasts (2002) Approved standard, 2nd edn. NCCLS document M27-A2. Wayne, PA: UCCLS

  18. Chirch L, Roche P, Fuhrer J (2008) Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole. Ear Nose Throat J 87:30–33

    PubMed  Google Scholar 

  19. Amonoo-Kuofi K, Tostevin P, Knight JR (2005) Aspergillus mastoiditis in a patient with systemic lupus erythematosus: a case report. Skull Base 15:109–112

    Article  PubMed  Google Scholar 

  20. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425

    Article  PubMed  CAS  Google Scholar 

  21. Kartsonis NA, Nielsen J, Douglas CM (2003) Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6:197–218

    Article  PubMed  CAS  Google Scholar 

  22. Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571

    Article  PubMed  CAS  Google Scholar 

  23. Walsh TJ, Teppler H, Donowitz GR et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402

    Article  PubMed  CAS  Google Scholar 

  24. Heinz WJ, Einsele H (2008) Caspofungin for treatment of invasive aspergillus infections. Mycoses 51:47–57

    Article  PubMed  CAS  Google Scholar 

  25. Boogaerts M, Winston DJ, Bow EJ et al (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 135:412–422

    PubMed  CAS  Google Scholar 

  26. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA (2003) Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41:3623–3626

    Article  PubMed  CAS  Google Scholar 

  27. Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    Article  PubMed  CAS  Google Scholar 

  28. Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571

    Article  PubMed  CAS  Google Scholar 

  29. Troke PF, Schwartz S, Ruhnke M et al. (2003) Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14–17, M-1755, p 476

  30. Serrano Mdel C, Valverde-Conde A, Chávez MM et al (2003) In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 45:131–135

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Abdullah Ayçiçek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ayçiçek, A., Çetinkaya, Z., Kiyici, H. et al. The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus . Eur Arch Otorhinolaryngol 266, 1703–1709 (2009). https://doi.org/10.1007/s00405-009-0963-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-009-0963-2

Keywords

Navigation